Denali Therapeutics Inc. (NASDAQ:DNLI) Receives $34.25 Average Price Target from Analysts

Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) have been given an average rating of “Moderate Buy” by the fifteen brokerages that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $34.25.

A number of equities research analysts have commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Denali Therapeutics in a report on Monday, April 20th. Deutsche Bank Aktiengesellschaft set a $31.00 price objective on Denali Therapeutics in a report on Friday, May 22nd. Jefferies Financial Group restated a “buy” rating and set a $40.00 price objective on shares of Denali Therapeutics in a report on Monday, March 2nd. Wolfe Research began coverage on Denali Therapeutics in a report on Monday, February 23rd. They set a “peer perform” rating on the stock. Finally, Leerink Partners decreased their price objective on Denali Therapeutics from $40.00 to $35.00 and set an “outperform” rating on the stock in a report on Wednesday, April 22nd.

Denali Therapeutics Stock Performance

DNLI opened at $21.04 on Monday. The stock has a market cap of $3.34 billion, a P/E ratio of -7.31 and a beta of 0.99. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.28 and a quick ratio of 9.28. The stock’s 50 day simple moving average is $19.73 and its 200 day simple moving average is $19.23. Denali Therapeutics has a 1-year low of $12.58 and a 1-year high of $23.77.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.69) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.04. During the same period last year, the firm posted ($0.78) earnings per share. As a group, equities analysts anticipate that Denali Therapeutics will post -2.74 EPS for the current fiscal year.

Institutional Investors Weigh In On Denali Therapeutics

Several hedge funds have recently made changes to their positions in the business. State of Wyoming raised its position in shares of Denali Therapeutics by 24.7% in the 4th quarter. State of Wyoming now owns 2,686 shares of the company’s stock worth $44,000 after buying an additional 532 shares during the period. Intrust Bank NA raised its position in shares of Denali Therapeutics by 5.6% in the 4th quarter. Intrust Bank NA now owns 11,164 shares of the company’s stock worth $184,000 after buying an additional 589 shares during the period. ADAR1 Capital Management LLC raised its position in shares of Denali Therapeutics by 1.2% in the 4th quarter. ADAR1 Capital Management LLC now owns 52,116 shares of the company’s stock worth $860,000 after buying an additional 600 shares during the period. PNC Financial Services Group Inc. raised its position in shares of Denali Therapeutics by 8.7% in the 1st quarter. PNC Financial Services Group Inc. now owns 9,220 shares of the company’s stock worth $177,000 after buying an additional 739 shares during the period. Finally, Pier 88 Investment Partners LLC raised its position in shares of Denali Therapeutics by 1.1% in the 4th quarter. Pier 88 Investment Partners LLC now owns 68,200 shares of the company’s stock worth $1,126,000 after buying an additional 760 shares during the period. Institutional investors and hedge funds own 92.92% of the company’s stock.

Denali Therapeutics Company Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.